Format

Send to

Choose Destination
Case Rep Oncol. 2018 Jul 16;11(2):485-492. doi: 10.1159/000490697. eCollection 2018 May-Aug.

Chronic Myeloid Leukemia with b3a3 (e14a3) Fusion: A Rare BCR/ABL Rearrangement Presenting with Thrombocytosis - Does MTHFR Polymorphism Matter.

Author information

1
Karmanos Cancer Institute at McLaren Oakland, Bloomfield Hills, Michigan, USA.
2
Department of Hematology/Oncology, McLaren Oakland Hospital, Michigan State University College of Osteopathic Medicine, Pontiac, Michigan, USA.
3
Department of Internal Medicine, McLaren Oakland Hospital, Michigan State University College of Osteopathic Medicine, Pontiac, Michigan, USA.

Abstract

Fusion of b2a2 is the most common BCR/ABL rearrangement in CML; however, absent a2 exons are very rare. We describe a case with Philadelphia-positive chronic myeloid leukemia (CML) with a very rare b3a3 (e14a3) BCR/ABL junction. To our knowledge, only 15 such cases of CML have previously been reported. These uncommon transcripts may be under-reported, since RT-PCR-based assays may fail to detect these fusions due to the location of the primers and probes used. We are reporting this case for the first time which presented with MTHFR mutation and significant thrombocytosis. There is very limited information on how this genotype expresses and responds to treatment, especially to tyrosine kinase inhibitors, as compared to classic CML. Also, the relationship between MTHFR mutation and CML is not clear, although studies have been done.

KEYWORDS:

BCR-ABL; Chronic myelogenous leukemia; b3a3; e14a3

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland Icon for PubMed Central
Loading ...
Support Center